Research Analysts Issue Forecasts for BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Northland Capmk issued their Q1 2026 earnings per share (EPS) estimates for BioLife Solutions in a report released on Monday, January 5th. Northland Capmk analyst C. Byrnes forecasts that the medical equipment provider will earn $0.01 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.03 EPS and FY2027 earnings at $0.25 EPS.

A number of other research firms also recently commented on BLFS. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a report on Monday. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $25.31 on Tuesday. The company has a market cap of $1.22 billion, a P/E ratio of -361.52 and a beta of 1.93. BioLife Solutions has a one year low of $19.10 and a one year high of $29.62. The business has a fifty day moving average of $25.59 and a two-hundred day moving average of $24.77.

Institutional Trading of BioLife Solutions

A number of hedge funds have recently made changes to their positions in BLFS. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $205,000. Forum Private Client Group LLC bought a new stake in shares of BioLife Solutions in the second quarter worth $232,000. Comerica Bank raised its holdings in BioLife Solutions by 5.2% in the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 746 shares in the last quarter. Royal Bank of Canada raised its holdings in BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock valued at $15,948,000 after acquiring an additional 617,320 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its stake in BioLife Solutions by 10.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 22,096 shares of the medical equipment provider’s stock valued at $475,000 after acquiring an additional 2,048 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 1,033 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total value of $25,959.29. Following the completion of the sale, the chief financial officer owned 151,736 shares of the company’s stock, valued at $3,813,125.68. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Amy Duross sold 2,000 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $24.60, for a total value of $49,200.00. Following the completion of the sale, the director owned 18,687 shares of the company’s stock, valued at approximately $459,700.20. This represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 937,664 shares of company stock worth $26,311,309 over the last 90 days. Company insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.